Cognitive Impairment and Quality of Life among Psychiatric Patients in Theparak Hospital, Nakhon Ratchasima
Article Sidebar
Main Article Content
Abstract
Objectives: To determine prevalence of cognitive impairment among psychiatric patients in Theparak Hospital, Nakhon Ratchasima and to compare quality of life between psychiatric patients who had and those who had no cognitive impairments. Methods: the study was a cross-sectional observational study in 290 patients under treatment. The study collected the data by conducting face-to-face interview with patients, reviewing patients’ medical charts and electronic database of those receiving care from psychiatric clinic in Theparak Hospital’s outpatient department. The patients’ cognitive function and quality of life were evaluated using the Rowland Universal Dementia Assessment Scale (RUDAS) and EuroQoL group-5 Dimensions (EQ-5D-5L) in Thai versions, respectively. Factors associated with quality of life were determined using multivariable analyses. Results: Participants’ average age was 51.2 years old. A total of 193 patients (66.6%) had cognitive impairment. Those with and those without impairment had the RUDAS scores of 19.3±4.0 and 26.0±2.0, respectively. In those diagnosed with schizophrenia, depression and other psychiatric conditions, the prevalence of impairment increased to 76.4, 61.0 and 62.5%, respectively. Propotion of patients with cognitive impairment reporting normal quality of life (no problem) was significantly lower than that of those having no impairment in the following dimensions, including mobility (57.5 vs. 86.6%; odds ratio, OR, 0.21; 95% CI 0.11-0.40), self-care (62.2 vs. 85.6%; OR, 0.28; 95% CI, 0.15-0.52) and usual activity (56.5 vs. 80.4%; OR, 0.32; 95% CI, 0.18-0.56). Differences of pain-discomfort and anxiety-depression between two subgroups were not statistically significant (33.2 vs. 36.1%; OR, 0.88; 95% CI, 0.53-1.47; 33.7 vs. 26.8%; OR, 1.39; 95% CI, 0.81-2.38, respectively). An overall quality of life in terms of utility among 290 psychiatric patients was 0.86±0.14. Factors associated with utility were presence of cognitive impairment (-0.043; 95% CI, -0.008 to -0.078), being diagnosed schizophrenia (-0.070; 95% CI, -0.111 to -0.278) and use of antidepressants (-0.052; 95% CI, -0.011 to -0.093). Conclusion: Cognitive impairment was common in psychiatric patients and was associated with decreasing quality of life of the patients. Additional factors affecting the quality of life included being schizophrenia and use of antidepressants.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
ผลการวิจัยและความคิดเห็นที่ปรากฏในบทความถือเป็นความคิดเห็นและอยู่ในความรับผิดชอบของผู้นิพนธ์ มิใช่ความเห็นหรือความรับผิดชอบของกองบรรณาธิการ หรือคณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์ ทั้งนี้ไม่รวมความผิดพลาดอันเกิดจากการพิมพ์ บทความที่ได้รับการเผยแพร่โดยวารสารเภสัชกรรมไทยถือเป็นสิทธิ์ของวารสารฯ
References
Phanthunane P, Whiteford H, Vos T, Bertram M. Economic burden of schizophrenia: empirical analyses from a survey in Thailand. J Ment Health Policy Econ 2012; 15: 25–32.
McDvory, JI, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Severe J. Effective ness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizo phrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006; 163: 600-10.
Aas M, Dazzan P, Mondelli V, Melle I, Murray RM, Pariante CM. A systematic review of cognitive function in first-episode psychosis, including a discussion on childhood trauma, stress, and inflamemation. Front Psychiatry 2014; 4: 182.
Zanelli J, Reichenberg A, Morgan K, Fearon P, Kravariti E, Dazzan P, et al. Specific and genera lized neuropsychological deficits: a comparison of patients with various first-episode psychosis presentations. Am J Psychiatry 2010; 167: 78–85.
Bagney A, Rodriguez-Jimenez R, Martinez-Gras I, Sanchez-Morla EM, Santos JL, Jimenez-Arriero MA, et al. Negative symptoms and executive function in schizophrenia: does their relationship change with illness duration. Psychopathology 2013; 46: 241–8.
Kubota M, van Haren NEM, Haijma SV, et al. Association of IQ changes and progressive brain changes in patients with schizophrenia. JAMA Psychiatry. 2015; 72: 803–12.
Szöke A, Trandafir A, Dupont ME, Méary A, Schürhoff F, Leboyer M. Longitudinal studies of cognition in schizophrenia: meta-analysis. Br J Psychiatry 2008; 192: 248-57.
Culpepper L, Lam RW, McIntyre RS. Cognitive impairment in patients with depression: Aware ness, Assessment, and Management. J Clin Psychiatry 2017; 78: 1383-94.
Gotra MY, Hill SK, Gershon ES, Tamminga CA, Ivleva EI, Pearlson GD, Keshavan MS, Clementz BA, McDowell JE, Buckley PF, Sweeney JA, Keedy SK. Distinguishing patterns of impairment on inhibitory control and general cognitive ability among bipolar with and without psychosis, schizo phrenia, and schizoaffective disorder. Schizophr Res 2020; 223: 148-157.
Limpawattana P, Tiamkao S, Sawanyawisuth K. The performance of the Rowland Universal Dementia Assessment Scale (RUDAS) for cognitive screening in a geriatric outpatient setting. Aging Clin Exp Res 2012; 24: 495-500.
Pattanaphesaj J, Thavorncharoensap M. Measure ment properties of the EQ-5D-5L compared to EQ-5D-3L in the Thai diabetes patients. Health Qual Life Outcomes 2015; 13: 14. doi: 10.1186/s12955-014-0203-3.
Wilson RS, Hebert LE, Evans DA. Educational attainment and cognitive decline in old age. Neuro logy 2009; 72: 460–5.
Jones RN, Gallo JJ. Education and sex differences in the Mini Mental State Examination. Effects of differential item functioning. J Gerontol B Psicol Sci Soc Sci 2002; 57: 548-58.
Perlick D, Stastny P, Katz I, Mayer M, Mattis S. Memory deficits and anticholinergic levels in chronic schizophrenia. Am J Psychiatry 1986; 143: 230-2.
Bullinger M, Kuhn J, Leopold K, Janetzky W, Wietfeld R. Lebensqualität als Zielkriterium in der Schizophrenietherapie [Quality of life as a target criterion in schizophrenia therapy]. Fortschr Neurol Psychiatr 2019; 87: 348-56.
Karow A, Wittmann L, Schöttle D, Schäfer I, Lambert M. The assessment of quality of life in clinical practice in patients with schizophrenia. Dialogues Clin Neurosci 2014; 16:185-95.
Rhee TG, Rosenheck RA. Does improvement in symptoms and quality of life in chronic schizo phrenia reduce family caregiver burden? Psychiatry Res 2019; 271: 402-4.
Sathienluckana T, Unaharassamee W, Suthisisang C, Suanchang O, Suansanae T. Anticholinergic discontinuation and cognitive functions in patients with schizophrenia: a pharmacist-physician collabo ration in the outpatient department. Integr Pharm Res Pract. 2018; 7: 161-71. doi:10.2147/IPRP.S17 6653
Ogino S, Miyamoto S, Tenjin T, Kitajima R, Ojima K, Miyake N, et al. Effects of discontinuation of long-term biperiden use on cognitive function and quality of life in schizophrenia. Prog Neuropsycho pharmacol Biol Psychiatry. 2011; 35: 78-83.
Folstein, MF, Folstein, SE, McHugh, PR. “Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician. Psychiatry Res 1975; 12: 189–98.
Nielsen TR, Vogel A, Gade A, Waldemar G. Cognitive testing in non-demented Turkish immi grants--comparison of the RUDAS and the MMSE. Scand J Psychol 2012; 53: 455-60.
Kittipongpisal S. Learning proficiency in schizo phrenic patients. Journal of Mental Health of Thai land 2013; 21: 185-197.
Limpawattana P, Tiamkao S, Sawanyawisuth K, Thinkhamrop B. Can Rowland Universal Dementia Assessment Scale (RUDAS) replace Mini-mental State Examination (MMSE) for dementia screening in a Thai geriatric outpatient setting? Am J Alzheimers Dis Other Demen 2012; 27: 254-9.
Monchi O, Petrides M, Petre V, Worsley K, Dagher A. Wisconsin Card Sorting revisited: distinct neural circuits participating in different stages of the task identified by event-related functional magnetic resonance imaging. J Neurosci 2001; 21: 7733-41.
Coulacoglou C, Saklofske DH. Executive function, theory of mind, and adaptive behavior. In: Coulaco glou C, Saklofske DH, editors. Psychometrics and psychological assessment. London: Academic Press; 2017.
Holmén A, Juuhl-Langseth M, Thormodsen R, Sundet K, Melle I, Rund BR. Executive function tests in early-onset psychosis: which one to choose? Scand J Psychol 2012; 53: 200-5.
Hou CL, Xiang YT, Wang ZL, Everall I, Tang Y, Yang C, Xu MZ, Correll CU, Jia FJ. Cognitive functioning in individuals at ultra-high risk for psychosis, first-degree relatives of patients with psychosis and patients with first-episode schizo phrenia. Schizophr Res 2016; 174: 71-6.
Nielsen RE, Levander S, KjaersdamTell_eus G, Jensen SOW, Østergaard, Christensen T, Leucht S. Second-generation antipsychotic effect on cognition in patients with schizophrenia—a meta-analysis of randomized clinical trials. Acta Psychiatr Scand 2015; 131: 185-96. doi: 10.1111/ acps.12374.
Thancharoen O, Waleekhachonloet O, Limwatta nanon C, Anutrakulchai S. Cognitive impairment, quality of life and healthcare utilization in patients with chronic kidney disease stages 3 to 5. Nephro logy 2020; 25: 625-33.
Limwattananon C, Limwattananon S, Waleekha chonloet O, Rattanachotphanit T. Cost-effective ness analysis of policy options on first-line treatments for advanced, non-small cell lung cancer in Thailand. Lung Cancer 2018; 120: 91-7.
Phumart P, Limwattananon C., Kitwitee P., Unnwongse K., Tiamkao S. EQ-5D-based utilities and healthcare utilization in Thai adults with chronic epilepsy. Epilepsy & Behavior 2018; 83: 140-6.
Cha’on U, Wongtrangan K, Thinkhamrop B, Tatiya nupanwong S, Limwattananon C, Pongskul C, Pan aput T, Chalermwat C, Lert-itthiporn W, Sharma A, Anutrakulchai S. CKDNET, a quality improvement project for prevention and reduction of chronic kidney disease in the Northeast Thailand. BMC Public Health 2020; 20:1299.
